A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension
← catalyst calendarSponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →.
Phase
Phase 1/2
Status
Completed
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
36actual
Sites
3
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-05 | actual | When the study began enrolling |
| Primary completion | 2025-07-17 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-07-17 | actual | The whole study's end, after follow-up |
| First posted | 2024-05-21 | actual | When this record first appeared on the registry |
| Results posted | 2026-04-30 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-04-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Mild to Moderate Hypertension
Interventions
- Drug: Zilebesiran — also filed as ALN-AGT01
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFNumber of Participants With Adverse Events (AEs)
measured Up to 12 months
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2024-10-18 · 1.7 MB · Prot_002.pdf
Statistical Analysis Planposted 2025-01-20 · 1.1 MB · SAP_003.pdf
Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed